The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Approaching bridging therapy decisions in patients with lymphoma undergoing CAR T-cell therapy
Megan Melody, MD, Tampa General Hospital, Tampa, FL, comments on the importance of bridging therapy in the CAR T-cell process, noting that it can improve outcomes by reducing metabolic tumor volume, but also highlighting that too many cycles of bridging therapy can have a negative impact. Dr Melody emphasizes the need to balance the benefits of bridging therapy with the potential risks of delaying CAR-T, and discusses various bridging therapy options available. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
